This Recommendation Statement from the US Preventive Services Task Force recommends that primary care professionals individualize the decision to refer adults without obesity and cardiovascular risk factors to behavioral counseling to promote healthful diet and physical activity (C recommendation).
This Evidence Report and systematic review to support a 2017 US Preventive Services Task Force Recommendation Statement summarizes current evidence on benefits and harms of behavioral counseling for primary prevention of cardiovascular disease (CVD) in adults without known CVD risk factors.
This Recommendation Statement from the US Preventive Services Task Force recommends use of low- to moderate-dose statins for primary prevention in adults aged 40 to 75 years who have 1 or more CVD risk factors and a calculated CVD event risk of 10% or greater (B recommendation).
This Viewpoint discusses the role of implementation and translational science and digital platforms for improving population cardiovascular risk and advancing precision treatments in an era of intensive statin therapy and PCSK9 inhibitors.
This Evidence Report and systematic review to support the 2016 US Preventive Services Task Force Recommendation Statement on use of statins for prevention of cardiovascular disease (CVD) summarizes published trial evidence about the benefits and harms of statins for primary CVD prevention.
This systematic review to support the 2016 update of the US Preventive Services Task Force Recommendation Statement on lipid screening in childhood and adolescence for detection of multifactorial dyslipidemia summarizes published evidence about the benefits and harms of screening.
This Recommendation Statement from the US Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger.
This Viewpoint discusses the need to achieve consensus around management strategies for patients with hyperlipidemia when proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors enter the marketplace.
This study uses Framingham cohort data to assess whether the 2013 American College of Cardiology/American Heart Association guidelines for cholesterol management improve identification of adults at higher risk of cardiovascular events compared with the 2004 Adult Treatment Panel III guidelines.
Ikeda and coauthors determine whether daily, low-dose aspirin reduces the incidence of cardiovascular (CV) events compared with no aspirin in older Japanese patients with multiple atherosclerotic risk factors.
You currently have no searches saved.